Bicara Therapeutics BCAX Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by Bicara Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:EmployeeRelatedLiabilitiesCurrent.
The official record: Bicara Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Bicara Therapeutics's accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Bicara Therapeutics's accrued expenses?
- Bicara Therapeutics (BCAX) reported accrued expenses of $1.91M in Q1 2026.
- How has Bicara Therapeutics's accrued expenses changed year-over-year?
- Bicara Therapeutics's accrued expenses increased by 14.1% year-over-year, from $1.68M to $1.91M.
- What is the long-term trend for Bicara Therapeutics's accrued expenses?
- Over 2 years (2023 to 2025), Bicara Therapeutics's accrued expenses has grown at a -20.9% compound annual growth rate (CAGR), from $8.05M to $5.04M.
- What does accrued expenses mean?
- Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.